Alan B. Lancz & Associates’s GSK GSK Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $376K | Sell |
9,780
-720
| -7% | -$27.6K | 0.38% | 71 |
|
|
2025
Q1 | $407K | Sell |
10,500
-120
| -1% | -$4.65K | 0.43% | 64 |
|
|
2024
Q4 | $359K | Sell |
10,620
-280
| -3% | -$9.47K | 0.36% | 72 |
|
|
2024
Q3 | $446K | Hold |
10,900
| – | – | 0.41% | 65 |
|
|
2024
Q2 | $420K | Buy |
+10,900
| New | +$420K | 0.41% | 63 |
|
|
2023
Q4 | $410K | Sell |
11,060
-300
| -3% | -$11.1K | 0.43% | 68 |
|
|
2023
Q3 | $412K | Sell |
11,360
-240
| -2% | -$8.7K | 0.47% | 59 |
|
|
2023
Q2 | $413K | Sell |
11,600
-80
| -0.7% | -$2.85K | 0.44% | 71 |
|
|
2023
Q1 | $416K | Buy |
11,680
+1,500
| +15% | +$53.4K | 0.43% | 69 |
|
|
2022
Q4 | $360K | Buy |
+10,180
| New | +$360K | 0.36% | 88 |
|
|
2022
Q2 | – | Sell |
-11,860
| Closed | -$646K | – | 188 |
|
|
2022
Q1 | $646K | Hold |
11,860
| – | – | 0.57% | 46 |
|
|
2021
Q4 | $654K | Buy |
+11,860
| New | +$654K | 0.57% | 48 |
|